HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Rejects Blood Glucose Health Claim For White Mulberry Supplement

Executive Summary

The UK Nutrition and Health Claims Committee has rejected the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for Ascarit’s white mulberry-based dietary supplement. 

You may also be interested in...



Blood Glucose Health Claim For Dietary Supplement Set For UK Assessment

Ascarit is seeking UK approval for the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for its white mulberry-based dietary supplement. It will be just the second claim assessed by the UK Nutrition and Health Claims Committee which took over the role from EFSA on 1 January 2021 following Brexit.

People On The Move: Appointments At Mayoly Spindler, Sanofi, Ceuta

A round-up of the latest appointments in Europe's health and wellness sector: Mayoly Spindler names leadership team following acquisition of Ipsen Consumer Healthcare; Sanofi unveils new Consumer Healthcare head for France; and ex-HRA Pharma CEO David Wright joins Ceuta Group.

Kidney Inflammation Warning For PPI Omeprazole In Europe

Cases of acute tubulointerstitial nephritis linked to omeprazole use flagged to the EMA leads to new product information warnings related to a possible risk of kidney inflammation for drugs containing the PPI sold in the EU.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel